Form 8-K · Current report
Steris 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001757898
- Accession no.
- 0001628280-26-053412
Summary
Steris reported fiscal 2027 first quarter revenue up 7% to $1.5 billion with adjusted diluted EPS of $2.59, and announced a targeted consolidation plan moving U.S. formulated chemistries manufacturing and distribution to a new Center of Excellence in North Carolina, closing facilities in St. Louis, Missouri and Plymouth, Minnesota. CEO Dan Carestio said the year's revenue and earnings expectations are unchanged; the company expects $55 million to $70 million in pre-tax restructuring charges with completion anticipated in fiscal 2030.
Key points
- Steris reported fiscal 2027 first quarter revenue of $1.5 billion, up 7% from $1.4 billion a year earlier, with constant currency organic growth of 6%.
- As reported diluted EPS was $2.04 and adjusted EPS was $2.59, versus $1.79 and $2.34 a year earlier; the company said its revenue and earnings expectations for the year are unchanged.
- The consolidation plan would close chemistry manufacturing and distribution facilities in St. Louis, Missouri, and Plymouth, Minnesota, and consolidate formulated chemistries production into a new Center of Excellence in North Carolina.
- Steris expects total pre-tax restructuring charges of about $55 million to $70 million, including $40 million to $50 million of cash expenditures, with completion anticipated during fiscal 2030.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 2.05Costs Associated with Exit or Disposal Activities
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 5, 2026, STERIS plc (the “Company” or "STERIS") issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.